Le Lézard
Classified in: Health
Subject: TRI

CAR-T Cell Immunotherapy Clinical Trial Cancer Patient in Remission; First-in-the-World Cancer Treatment Shows Promise


MILWAUKEE, Feb. 7, 2018 /PRNewswire-USNewswire/ -- Physicians and clinical researchers from the Medical College of Wisconsin (MCW), Froedtert Hospital, Children's Hospital of Wisconsin, and BloodCenter of Wisconsin have successfully used a new immunology treatment, chimeric antigen receptor (CAR) T-cell therapy, to extend the life of a 52-year-old Wisconsin man.

Caption: Physicians and clinical researchers from the Medical College of Wisconsin (MCW), Froedtert Hospital, Children's Hospital of Wisconsin, and BloodCenter of Wisconsin have successfully used a new immunology treatment, chimeric antigen receptor (CAR) T-cell therapy, to extend the life of a 52-year-old Wisconsin man.

Bret C., 52, of Appleton, Wis., is the first patient to participate in this novel clinical trial. He was diagnosed with mantle cell lymphoma, a cancer of the immune system, in 2011. Despite chemotherapy, stem cell transplants, medications and other clinical trials, his cancer kept returning. When presented with the dual-targeted CAR-T cell immunotherapy clinical trial option in late 2017, just weeks after a similar treatment had been approved by the FDA, Bret recognized it as the best opportunity to extend his life and agreed to participate. He received the CAR-T cell dose in late October, and just six weeks later, his cancer was no longer detectable in his body.

The new treatment genetically alters a person's immune system to uniquely personalize it to target cancer cells, a significant departure from more routine chemotherapy.

While CAR-T cell therapy has been under development since 2012, the patient treated at Froedtert & the Medical College of Wisconsin Clinical Cancer Center is the first patient to participate in the first-ever, clinical trial for a novel dual-targeted CAR-T cell therapy against CD19 and CD20 that was manufactured using the CliniMACS Prodigy® device, which is part of an automated CAR-T cell manufacturing platform developed by Miltenyi Biotec GmbH, a global company dedicated to enabling cellular and gene therapies. The dual-targeted CD19 and CD20 targeted CAR vector used to generate the CAR-T cells was developed and manufactured by Lentigen Technology, Inc., a subsidiary of Miltenyi Biotec GmbH. The modified cells can identify cancerous cells, attach to the cancer cells, and effectively destroy the cancer cells. A separate pediatric clinical trial for CAR-T treatment at Children's Hospital of Wisconsin is expected to start later this year.

To continue reading the story, request broll and / or photos, visit: https://newsroom.mcw.edu/news-articles/cart-cell-immunotherapy-clinical-trial-cancer-patient-in-remission

Broll and photos available by request.

 

SOURCE Medical College of Wisconsin


These press releases may also interest you

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...



News published on and distributed by: